ID   MFHA1_HUMAN             Reviewed;        1052 AA.
AC   Q9Y4C4; Q96CI0;
DT   23-OCT-2007, integrated into UniProtKB/Swiss-Prot.
DT   18-MAY-2010, sequence version 2.
DT   28-JUN-2023, entry version 156.
DE   RecName: Full=Malignant fibrous histiocytoma-amplified sequence 1 {ECO:0000305};
DE   AltName: Full=Malignant fibrous histiocytoma-amplified sequence with leucine-rich tandem repeats 1 {ECO:0000303|PubMed:9973190};
GN   Name=MFHAS1 {ECO:0000312|HGNC:HGNC:16982};
GN   Synonyms=MASL1 {ECO:0000303|PubMed:9973190};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], TISSUE SPECIFICITY, AND VARIANT PRO-892.
RC   TISSUE=Fetal brain;
RX   PubMed=9973190;
RA   Sakabe T., Shinomiya T., Mori T., Ariyama Y., Fukuda Y., Fujiwara T.,
RA   Nakamura Y., Inazawa J.;
RT   "Identification of a novel gene, MASL1, within an amplicon at 8p23.1
RT   detected in malignant fibrous histiocytomas by comparative genomic
RT   hybridization.";
RL   Cancer Res. 59:511-515(1999).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16421571; DOI=10.1038/nature04406;
RA   Nusbaum C., Mikkelsen T.S., Zody M.C., Asakawa S., Taudien S., Garber M.,
RA   Kodira C.D., Schueler M.G., Shimizu A., Whittaker C.A., Chang J.L.,
RA   Cuomo C.A., Dewar K., FitzGerald M.G., Yang X., Allen N.R., Anderson S.,
RA   Asakawa T., Blechschmidt K., Bloom T., Borowsky M.L., Butler J., Cook A.,
RA   Corum B., DeArellano K., DeCaprio D., Dooley K.T., Dorris L. III,
RA   Engels R., Gloeckner G., Hafez N., Hagopian D.S., Hall J.L., Ishikawa S.K.,
RA   Jaffe D.B., Kamat A., Kudoh J., Lehmann R., Lokitsang T., Macdonald P.,
RA   Major J.E., Matthews C.D., Mauceli E., Menzel U., Mihalev A.H.,
RA   Minoshima S., Murayama Y., Naylor J.W., Nicol R., Nguyen C., O'Leary S.B.,
RA   O'Neill K., Parker S.C.J., Polley A., Raymond C.K., Reichwald K.,
RA   Rodriguez J., Sasaki T., Schilhabel M., Siddiqui R., Smith C.L.,
RA   Sneddon T.P., Talamas J.A., Tenzin P., Topham K., Venkataraman V., Wen G.,
RA   Yamazaki S., Young S.K., Zeng Q., Zimmer A.R., Rosenthal A., Birren B.W.,
RA   Platzer M., Shimizu N., Lander E.S.;
RT   "DNA sequence and analysis of human chromosome 8.";
RL   Nature 439:331-335(2006).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 383-1052, AND VARIANT PRO-892.
RC   TISSUE=B-cell;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [4]
RP   DISEASE, AND CHROMOSOMAL TRANSLOCATION WITH 14Q21 ELEMENT.
RX   PubMed=14691450; DOI=10.1038/sj.onc.1207352;
RA   Tagawa H., Karnan S., Kasugai Y., Tuzuki S., Suzuki R., Hosokawa Y.,
RA   Seto M.;
RT   "MASL1, a candidate oncogene found in amplification at 8p23.1, is
RT   translocated in immunoblastic B-cell lymphoma cell line OCI-LY8.";
RL   Oncogene 23:2576-2581(2004).
RN   [5]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-601, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19608861; DOI=10.1126/science.1175371;
RA   Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M., Walther T.C.,
RA   Olsen J.V., Mann M.;
RT   "Lysine acetylation targets protein complexes and co-regulates major
RT   cellular functions.";
RL   Science 325:834-840(2009).
RN   [6]
RP   INDUCTION.
RX   PubMed=20616063; DOI=10.1073/pnas.1000093107;
RA   Ng A.C., Eisenberg J.M., Heath R.J., Huett A., Robinson C.M., Nau G.J.,
RA   Xavier R.J.;
RT   "Human leucine-rich repeat proteins: a genome-wide bioinformatic
RT   categorization and functional analysis in innate immunity.";
RL   Proc. Natl. Acad. Sci. U.S.A. 108:4631-4638(2011).
RN   [7]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY
RP   [LARGE SCALE ANALYSIS].
RX   PubMed=22814378; DOI=10.1073/pnas.1210303109;
RA   Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A.,
RA   Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E., Timmerman E.,
RA   Prieto J., Arnesen T., Sherman F., Gevaert K., Aldabe R.;
RT   "N-terminal acetylome analyses and functional insights of the N-terminal
RT   acetyltransferase NatB.";
RL   Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012).
RN   [8]
RP   FUNCTION, INTERACTION WITH RAF1, TISSUE SPECIFICITY, INDUCTION, AND
RP   MUTAGENESIS OF 414-LEU--ARG-556 AND SER-450.
RX   PubMed=23327923; DOI=10.1182/blood-2011-10-385252;
RA   Kumkhaek C., Aerbajinai W., Liu W., Zhu J., Uchida N., Kurlander R.,
RA   Hsieh M.M., Tisdale J.F., Rodgers G.P.;
RT   "MASL1 induces erythroid differentiation in human erythropoietin-dependent
RT   CD34+ cells through the Raf/MEK/ERK pathway.";
RL   Blood 121:3216-3227(2013).
RN   [9]
RP   GTP-BINDING, INTERACTION WITH HSPD1, SUBCELLULAR LOCATION, AND MUTAGENESIS
RP   OF LYS-443.
RX   PubMed=24286120; DOI=10.1111/febs.12593;
RA   Dihanich S., Civiero L., Manzoni C., Mamais A., Bandopadhyay R.,
RA   Greggio E., Lewis P.A.;
RT   "GTP binding controls complex formation by the human ROCO protein MASL1.";
RL   FEBS J. 281:261-274(2014).
RN   [10]
RP   FUNCTION, AND INDUCTION.
RX   PubMed=26599367; DOI=10.1371/journal.pone.0143662;
RA   Zhong J., Shi Q.Q., Zhu M.M., Shen J., Wang H.H., Ma D., Miao C.H.;
RT   "MFHAS1 is associated with sepsis and stimulates TLR2/NF-kappaB signaling
RT   pathway following negative regulation.";
RL   PLoS ONE 10:E0143662-E0143662(2015).
RN   [11]
RP   FUNCTION, INTERACTION WITH PJA2, UBIQUITINATION BY PJA2, AND REGION.
RX   PubMed=28471450; DOI=10.1038/cddis.2017.102;
RA   Zhong J., Wang H., Chen W., Sun Z., Chen J., Xu Y., Weng M., Shi Q., Ma D.,
RA   Miao C.;
RT   "Ubiquitylation of MFHAS1 by the ubiquitin ligase praja2 promotes M1
RT   macrophage polarization by activating JNK and p38 pathways.";
RL   Cell Death Dis. 8:E2763-E2763(2017).
RN   [12]
RP   FUNCTION, INTERACTION WITH PPP2CA AND PPP2R2A, AND REGION.
RX   PubMed=28609714; DOI=10.1016/j.molimm.2017.06.017;
RA   Shi Q., Xiong B., Zhong J., Wang H., Ma D., Miao C.;
RT   "MFHAS1 suppresses TLR4 signaling pathway via induction of PP2A C subunit
RT   cytoplasm translocation and inhibition of c-Jun dephosphorylation at
RT   Thr239.";
RL   Mol. Immunol. 88:79-88(2017).
RN   [13]
RP   FUNCTION, AND INDUCTION.
RX   PubMed=29168081; DOI=10.1007/s10753-017-0696-0;
RA   Wang H.H., Sun P.F., Chen W.K., Zhong J., Shi Q.Q., Weng M.L., Ma D.,
RA   Miao C.H.;
RT   "High Glucose Stimulates Expression of MFHAS1 to Mitigate Inflammation via
RT   Akt/HO-1 Pathway in Human Umbilical Vein Endothelial Cells.";
RL   Inflammation 41:400-408(2018).
CC   -!- FUNCTION: Probable GTP-binding protein (PubMed:24286120). Functions in
CC       innate immunity and more specifically the inflammatory response as a
CC       regulator of the Toll-like receptor TLR2 and TLR4 signaling pathways
CC       (PubMed:26599367, PubMed:28471450, PubMed:28609714). Negatively
CC       regulates the part of the TLR4 signaling pathway that leads to the
CC       activation of the transcription factor AP-1. By retaining the
CC       phosphatase complex PP2A into the cytoplasm, prevents the
CC       dephosphorylation of the AP-1 subunit JUN which is required for proper
CC       activation of the transcription factor (PubMed:28609714). Both inhibits
CC       and activates the TLR2-dependent signaling pathway (PubMed:26599367).
CC       Positively regulates the TLR2 signaling pathway to activate
CC       specifically the downstream p38 and JNK MAP kinases and promote the
CC       polarization of macrophages toward the pro-inflammatory M1 phenotype
CC       (PubMed:28471450). It may also play a role in the regulation of
CC       inflammation induced by high glucose through the PKB/AKT signaling
CC       pathway (PubMed:29168081). Also involved in erythrocyte differentiation
CC       through activation of the ERK1/ERK2 signaling pathway
CC       (PubMed:23327923). {ECO:0000269|PubMed:23327923,
CC       ECO:0000269|PubMed:24286120, ECO:0000269|PubMed:26599367,
CC       ECO:0000269|PubMed:28471450, ECO:0000269|PubMed:28609714,
CC       ECO:0000269|PubMed:29168081}.
CC   -!- SUBUNIT: Interacts with RAF1 (PubMed:23327923). Interacts with HSPD1
CC       (PubMed:24286120). Interacts with PPP2CA; retains PPP2CA into the
CC       cytoplasm and excludes it from the nucleus (PubMed:28609714). Interacts
CC       with PPP2R2A; the interaction is direct (PubMed:28609714). Interacts
CC       with PJA2 (PubMed:28471450). {ECO:0000269|PubMed:23327923,
CC       ECO:0000269|PubMed:24286120, ECO:0000269|PubMed:28471450,
CC       ECO:0000269|PubMed:28609714}.
CC   -!- INTERACTION:
CC       Q9Y4C4; P10809: HSPD1; NbExp=3; IntAct=EBI-2864441, EBI-352528;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:24286120}.
CC   -!- TISSUE SPECIFICITY: Ubiquitously expressed. Overexpressed in malignant
CC       fibrous histiocytomas (PubMed:9973190). Expressed in red blood cells
CC       (at protein level) (PubMed:23327923). {ECO:0000269|PubMed:23327923,
CC       ECO:0000269|PubMed:9973190}.
CC   -!- INDUCTION: Up-regulated during erythroid cells differentiation (at
CC       protein level) (PubMed:23327923). Up-regulated upon Toll-like receptor
CC       TLR2 stimulation (PubMed:26599367). Up-regulated in macrophages upon M.
CC       tuberculosis infection (PubMed:20616063). Up-regulated upon sepsis
CC       (PubMed:26599367). Up-regulated by glucose (PubMed:29168081).
CC       {ECO:0000269|PubMed:20616063, ECO:0000269|PubMed:23327923,
CC       ECO:0000269|PubMed:26599367, ECO:0000269|PubMed:29168081}.
CC   -!- PTM: Ubiquitinated. Ubiquitination by PJA2 does not lead MFHAS1 to
CC       proteasomal degradation but positively regulates its function in
CC       polarization of macrophages. {ECO:0000269|PubMed:28471450}.
CC   -!- DISEASE: Note=A chromosomal aberration involving MFHAS1 may be a cause
CC       of B-cell lymphoma. Translocation t(8;14)(p23.1;q21) with a cryptic
CC       exon named '14q21 element'. The resulting fusion protein named
CC       'chimeric MASL1' is tumorigenic in nude mice.
CC       {ECO:0000269|PubMed:14691450}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AB016816; BAA74737.1; -; mRNA.
DR   EMBL; AC090567; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC014226; AAH14226.2; -; mRNA.
DR   CCDS; CCDS34844.1; -.
DR   RefSeq; NP_004216.2; NM_004225.2.
DR   AlphaFoldDB; Q9Y4C4; -.
DR   SMR; Q9Y4C4; -.
DR   BioGRID; 114681; 128.
DR   IntAct; Q9Y4C4; 94.
DR   MINT; Q9Y4C4; -.
DR   STRING; 9606.ENSP00000276282; -.
DR   GlyGen; Q9Y4C4; 2 sites, 1 O-linked glycan (2 sites).
DR   iPTMnet; Q9Y4C4; -.
DR   PhosphoSitePlus; Q9Y4C4; -.
DR   BioMuta; MFHAS1; -.
DR   DMDM; 296437367; -.
DR   EPD; Q9Y4C4; -.
DR   jPOST; Q9Y4C4; -.
DR   MassIVE; Q9Y4C4; -.
DR   MaxQB; Q9Y4C4; -.
DR   PaxDb; Q9Y4C4; -.
DR   PeptideAtlas; Q9Y4C4; -.
DR   ProteomicsDB; 86160; -.
DR   Antibodypedia; 65867; 28 antibodies from 9 providers.
DR   DNASU; 9258; -.
DR   Ensembl; ENST00000276282.7; ENSP00000276282.6; ENSG00000147324.11.
DR   GeneID; 9258; -.
DR   KEGG; hsa:9258; -.
DR   MANE-Select; ENST00000276282.7; ENSP00000276282.6; NM_004225.3; NP_004216.2.
DR   UCSC; uc003wsj.2; human.
DR   AGR; HGNC:16982; -.
DR   CTD; 9258; -.
DR   DisGeNET; 9258; -.
DR   GeneCards; MFHAS1; -.
DR   HGNC; HGNC:16982; MFHAS1.
DR   HPA; ENSG00000147324; Low tissue specificity.
DR   MIM; 605352; gene.
DR   neXtProt; NX_Q9Y4C4; -.
DR   OpenTargets; ENSG00000147324; -.
DR   PharmGKB; PA30773; -.
DR   VEuPathDB; HostDB:ENSG00000147324; -.
DR   eggNOG; KOG0619; Eukaryota.
DR   GeneTree; ENSGT00940000158928; -.
DR   HOGENOM; CLU_320767_0_0_1; -.
DR   InParanoid; Q9Y4C4; -.
DR   OMA; IVCPKNG; -.
DR   OrthoDB; 5352941at2759; -.
DR   PhylomeDB; Q9Y4C4; -.
DR   TreeFam; TF351429; -.
DR   PathwayCommons; Q9Y4C4; -.
DR   SignaLink; Q9Y4C4; -.
DR   BioGRID-ORCS; 9258; 12 hits in 1154 CRISPR screens.
DR   ChiTaRS; MFHAS1; human.
DR   GenomeRNAi; 9258; -.
DR   Pharos; Q9Y4C4; Tbio.
DR   PRO; PR:Q9Y4C4; -.
DR   Proteomes; UP000005640; Chromosome 8.
DR   RNAct; Q9Y4C4; protein.
DR   Bgee; ENSG00000147324; Expressed in saphenous vein and 185 other tissues.
DR   Genevisible; Q9Y4C4; HS.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005525; F:GTP binding; IDA:UniProtKB.
DR   GO; GO:0051721; F:protein phosphatase 2A binding; IDA:UniProtKB.
DR   GO; GO:0031625; F:ubiquitin protein ligase binding; IPI:UniProtKB.
DR   GO; GO:0030218; P:erythrocyte differentiation; IMP:UniProtKB.
DR   GO; GO:0006954; P:inflammatory response; IMP:UniProtKB.
DR   GO; GO:0045087; P:innate immune response; IMP:UniProtKB.
DR   GO; GO:0050728; P:negative regulation of inflammatory response; IMP:UniProtKB.
DR   GO; GO:0035308; P:negative regulation of protein dephosphorylation; IMP:UniProtKB.
DR   GO; GO:1900181; P:negative regulation of protein localization to nucleus; IMP:UniProtKB.
DR   GO; GO:0034136; P:negative regulation of toll-like receptor 2 signaling pathway; IMP:UniProtKB.
DR   GO; GO:0034144; P:negative regulation of toll-like receptor 4 signaling pathway; IMP:UniProtKB.
DR   GO; GO:0070374; P:positive regulation of ERK1 and ERK2 cascade; IMP:UniProtKB.
DR   GO; GO:0046330; P:positive regulation of JNK cascade; IMP:UniProtKB.
DR   GO; GO:1900745; P:positive regulation of p38MAPK cascade; IMP:UniProtKB.
DR   GO; GO:0051897; P:positive regulation of protein kinase B signaling; IMP:UniProtKB.
DR   GO; GO:0034137; P:positive regulation of toll-like receptor 2 signaling pathway; IMP:UniProtKB.
DR   GO; GO:0043030; P:regulation of macrophage activation; IMP:UniProtKB.
DR   GO; GO:0034121; P:regulation of toll-like receptor signaling pathway; IEA:Ensembl.
DR   Gene3D; 3.40.50.300; P-loop containing nucleotide triphosphate hydrolases; 1.
DR   Gene3D; 3.80.10.10; Ribonuclease Inhibitor; 2.
DR   Gene3D; 3.30.70.1390; ROC domain from the Parkinson's disease-associated leucine-rich repeat kinase 2; 1.
DR   InterPro; IPR001611; Leu-rich_rpt.
DR   InterPro; IPR003591; Leu-rich_rpt_typical-subtyp.
DR   InterPro; IPR032675; LRR_dom_sf.
DR   InterPro; IPR027417; P-loop_NTPase.
DR   InterPro; IPR020859; ROC_dom.
DR   PANTHER; PTHR48051; -; 1.
DR   PANTHER; PTHR48051:SF1; NON-SPECIFIC SERINE/THREONINE PROTEIN KINASE-RELATED; 1.
DR   Pfam; PF13855; LRR_8; 3.
DR   Pfam; PF08477; Roc; 1.
DR   PRINTS; PR00019; LEURICHRPT.
DR   SMART; SM00364; LRR_BAC; 11.
DR   SMART; SM00365; LRR_SD22; 5.
DR   SMART; SM00369; LRR_TYP; 13.
DR   SUPFAM; SSF52058; L domain-like; 1.
DR   SUPFAM; SSF52540; P-loop containing nucleoside triphosphate hydrolases; 1.
DR   SUPFAM; SSF82615; Polo-box domain; 1.
DR   PROSITE; PS51450; LRR; 12.
DR   PROSITE; PS51424; ROC; 1.
PE   1: Evidence at protein level;
KW   Acetylation; Chromosomal rearrangement; Cytoplasm; GTP-binding; Immunity;
KW   Inflammatory response; Innate immunity; Leucine-rich repeat;
KW   Nucleotide-binding; Reference proteome; Repeat;
KW   Signal transduction inhibitor; Tumor suppressor; Ubl conjugation.
FT   INIT_MET        1
FT                   /note="Removed"
FT                   /evidence="ECO:0007744|PubMed:22814378"
FT   CHAIN           2..1052
FT                   /note="Malignant fibrous histiocytoma-amplified sequence 1"
FT                   /id="PRO_0000308609"
FT   REPEAT          64..85
FT                   /note="LRR 1"
FT   REPEAT          88..109
FT                   /note="LRR 2"
FT   REPEAT          112..133
FT                   /note="LRR 3"
FT   REPEAT          136..157
FT                   /note="LRR 4"
FT   REPEAT          159..180
FT                   /note="LRR 5"
FT   REPEAT          182..203
FT                   /note="LRR 6"
FT   REPEAT          205..226
FT                   /note="LRR 7"
FT   REPEAT          228..249
FT                   /note="LRR 8"
FT   REPEAT          251..272
FT                   /note="LRR 9"
FT   REPEAT          274..296
FT                   /note="LRR 10"
FT   REPEAT          297..318
FT                   /note="LRR 11"
FT   REPEAT          320..341
FT                   /note="LRR 12"
FT   REPEAT          343..364
FT                   /note="LRR 13"
FT   DOMAIN          403..649
FT                   /note="Roc"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00758"
FT   REGION          64..649
FT                   /note="Required for interaction with PPP2R2A"
FT                   /evidence="ECO:0000269|PubMed:28609714"
FT   REGION          64..364
FT                   /note="Required for interaction with PJA2"
FT                   /evidence="ECO:0000269|PubMed:28471450"
FT   SITE            1000..1001
FT                   /note="Breakpoint for translocation to form chimeric MASL1"
FT   MOD_RES         2
FT                   /note="N-acetylalanine"
FT                   /evidence="ECO:0007744|PubMed:22814378"
FT   MOD_RES         601
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0007744|PubMed:19608861"
FT   VARIANT         163
FT                   /note="L -> V (in dbSNP:rs34984230)"
FT                   /id="VAR_036846"
FT   VARIANT         892
FT                   /note="L -> P (in dbSNP:rs429433)"
FT                   /evidence="ECO:0000269|PubMed:15489334,
FT                   ECO:0000269|PubMed:9973190"
FT                   /id="VAR_036847"
FT   MUTAGEN         414..556
FT                   /note="Missing: Dominant negative effect on the ERK1/ERK2
FT                   signaling pathway and EPO-induced erythroid
FT                   differentiation."
FT                   /evidence="ECO:0000269|PubMed:23327923"
FT   MUTAGEN         443
FT                   /note="K->A: Loss of GTP-binding."
FT                   /evidence="ECO:0000269|PubMed:24286120"
FT   MUTAGEN         450
FT                   /note="S->A: Dominant negative effect on the ERK1/ERK2
FT                   signaling pathway and EPO-induced erythroid
FT                   differentiation."
FT                   /evidence="ECO:0000269|PubMed:23327923"
FT   CONFLICT        529
FT                   /note="H -> N (in Ref. 1; BAA74737)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   1052 AA;  116950 MW;  D68AB60DEC5F6653 CRC64;
     MAGMDSGNLK TARLWRDAAL RARKLRSNLR QLTLTAAGAC PGAGADALES PASPQLVLPA
     NLGDIEALNL GNNGLEEVPE GLGSALGSLR VLVLRRNRFA RLPPAVAELG HHLTELDVSH
     NRLTALGAEV VSALRELRKL NLSHNQLPAL PAQLGALAHL EELDVSFNRL AHLPDSLSCL
     SRLRTLDVDH NQLTAFPRQL LQLVALEELD VSSNRLRGLP EDISALRALK ILWLSGAELG
     TLPAGFCELA SLESLMLDNN GLQALPAQFS CLQRLKMLNL SSNLFEEFPA ALLPLAGLEE
     LYLSRNQLTS VPSLISGLGR LLTLWLDNNR IRYLPDSIVE LTGLEELVLQ GNQIAVLPDH
     FGQLSRVGLW KIKDNPLIQP PYEVCMKGIP YIAAYQKELA HSQPAVQPRL KLLLMGHKAA
     GKTLLRHCLT EERVEGCPGG GDKEKCYPPS PPPVSKGIEV TSWTADASRG LRFIVYDLAG
     DESYEVIQPF FLSPGALYVL VVNLATYEPR HFPTTVGSFL HRVGARVPHA VVCIVGTHAD
     LCGERELEEK CLDIHRQIAL QEKHDAEGLS RLAKVVDEAL ARDFELRSAS PHAAYYGVSD
     KNLRRRKAHF QYLLNHRLQI LSPVLPVSCR DPRHLRRLRD KLLSVAEHRE IFPNLHRVLP
     RSWQVLEELH FQPPQAQRLW LSWWDSARLG LQAGLTEDRL QSALSYLHES GKLLYFEDSP
     ALKEHVFHNL TRLIDILNVF FQRDPSLLLH KLLLGTSGEG KAEGESSPPM ARSTPSQELL
     RATQLHQYVE GFLLHGLLPA HVIRLLLKPH VQAQQDLQLL LELLEKMGLC YCLNKPKGKP
     LNGSTAWYKF PCYVQNEVPH AEAWINGTNL AGQSFVAEQL QIEYSFPFTF PLGLFARYSV
     QINSHVVHRS DGKFQIFAYR GKVPVVVSYR PARGVLQPDT LSIASHASLP NIWTAWQAIT
     PLVEELNVLL QEWPGLHYTV HILCSKCLKR GSPNPHAFPG ELLSQPRPEG VAEIICPKNG
     SERVNVALVY PPTPTVISPC SKKNVGEKHR NQ
//
